• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

VIS Quiz Question #4

Poll

4. Which of the following regarding methods of distributing a VIS to a parent/guardian is FALSE?

A. A parent can be given a laminated VIS copy to look at, but has to be offered a hard copy to take home
B. A parent can be sent a copy of the VIS electronically days before the visit
C. A parent/guardian may view the VIS on a computer monitor or other video display prior to vaccine administration
D. The physician can send a physical letter to the parent/guardian that provides a link (URL) to an online VIS
E. None of the above
Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial / image credit ©Justlight AI/stock.adobe.com

Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial

Grace Halsey
January 29th 2025
Article

Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study / image credit ©Dx Photo/stock.adobe.com

Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study

Grace Halsey
January 29th 2025
Article

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD

FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD

Sydney Jennings
January 28th 2025
Article

This newest approval established Ozempic as the most broadly indicted GLP-1 RA in its class.

Dementia Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET

Alzheimer Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET

Grace Halsey
January 28th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.